38.35

0.76% 0.29

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $38.35, with a volume of 250.81K. It is up +0.76% in the last 24 hours and up +24.31% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$38.06

Open:

$38.05

24h Volume:

250.81K

Relative Volume:

0.49

Market Cap:

$819.65M

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-4.1821

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

-4.70%

1M Performance:

+24.31%

6M Performance:

-50.75%

1Y Performance:

-23.44%

1-Day Range:

$37.97

$39.40

1-Week Range:

$34.89

$40.89

52-Week Range:

$26.70

$91.83

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	38.35	819.65M	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

10:10 AM

Praxis Precision Medicines (NASDAQ:PRAX) Research Coverage Started at Chardan Capital - Defense World

10:10 AM

02:37 AM

Praxis Precision Medicines (PRAX) to Release Earnings on Monday - Defense World

02:37 AM

May 09, 2025

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

May 09, 2025

May 08, 2025

Analytical Lens: Exploring Praxis Precision Medicines Inc (PRAX)’s Financial Story Through Ratios - DWinneX

May 08, 2025

3,008 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Bought by Envestnet Asset Management Inc. - Defense World

May 08, 2025

HC Wainwright Issues Negative Forecast for PRAX Earnings - Defense World

May 08, 2025

Wedbush Has Positive Outlook for PRAX Q2 Earnings - Defense World

May 08, 2025

May 07, 2025

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga

May 07, 2025

Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq

May 07, 2025

This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

May 07, 2025

Chardan Capital Initiates Coverage on PRAX with a Buy Rating | PRAX Stock News - GuruFocus

May 07, 2025

Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target - marketscreener.com

May 07, 2025

Chardan Initiates Coverage on Praxis Precision (PRAX) with Buy Rating | PRAX Stock News - GuruFocus

May 07, 2025

Analysts Issue Forecasts for PRAX Q4 Earnings - Defense World

May 07, 2025

HC Wainwright Has Bearish Forecast for PRAX FY2029 Earnings - Defense World

May 07, 2025

May 06, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Given New $28.00 Price Target at Wedbush - Defense World

May 06, 2025

Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail

May 06, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Receives “Buy” Rating from Needham & Company LLC - Defense World

May 06, 2025

Praxis Precision Medicines: Advancements and Financial Outlook - TipRanks

May 06, 2025

May 05, 2025

Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX - GuruFocus

May 05, 2025

Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus

May 05, 2025

PRAX Stock Target Increased by Baird Amid Positive Epilepsy Drug Outlook | PRAX Stock News - GuruFocus

May 05, 2025

Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating - marketscreener.com

May 05, 2025

PRAX Unveils Progress in DEE Clinical Programs | PRAX Stock News - GuruFocus

May 05, 2025

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event - The Manila Times

May 05, 2025

Clinical Trial Success: Praxis's DEE Drug Cuts Seizures by 90%, Eyes $3B Market Opportunity - Stock Titan

May 05, 2025

Praxis Precision Medicine (PRAX): Buy Rating Reiterated by Needham | PRAX Stock News - GuruFocus

May 05, 2025

May 04, 2025

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024) - Yahoo Finance

May 04, 2025

May 02, 2025

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PRAX Stock News - GuruFocus

May 02, 2025

Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 02, 2025

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 02, 2025

Praxis Precision Medicines Awards 3,688 Restricted Stock Units to 5 New Non-Executive Hires - Stock Titan

May 02, 2025

Praxis Precision Medicines Provides Corporate Update and Reports - GuruFocus

May 02, 2025

PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfoli - GuruFocus

May 02, 2025

PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfolio | PRAX Stock News - GuruFocus

May 02, 2025

Praxis Precision Medicines, Inc. SEC 10-Q Report - TradingView

May 02, 2025

Praxis Precision Medicines Reports Significant Progress and Upcoming Milestones in Epilepsy Portfolio - Nasdaq

May 02, 2025

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 02, 2025

Praxis Financial Results: Major Clinical Pipeline Progress with $472M War Chest Extending to 2028 - Stock Titan

May 02, 2025

Wells Fargo & Company MN Boosts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World

May 02, 2025

May 01, 2025

Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts - Benzinga

May 01, 2025

PRAX: HC Wainwright Reiterates Buy Rating and $105 Price Target | PRAX Stock News - GuruFocus

May 01, 2025